Safety and Efficacy of Allogenic CD19-CAR-NK Cells in Treatmenting r/r B-cell Hematologic Malignancies

Clinical trial NCT05739227 · UNKNOWN

Trial details

NCT number: NCT05739227
Sponsor: Xuzhou Medical University
Status: UNKNOWN
Phase: Early Phase 1
Study type: INTERVENTIONAL

Acute Lymphoblastic Leukemia B-cell Lymphoma Chronic Lymphocytic Leukemia

Start date: 2023-03-01
Primary completion: 2025-05-01
Enrollment: 12

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.